GlassScriptPhysician profile
Matthew J Hoermann
NPI 1790770634
$5,546.43
in general payments reported to CMS, 2019-2025
38 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $604 · 2021: $1,024 · 2022: $714 · 2023: $913 · 2024: $1,071 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.31 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,039.52 | 2019-2025 | |
| Lilly USA, LLC | $550.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $379.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $352.81 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $348.68 | 2019-2024 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.56 | 2019-2025 | Xifaxan |
| Allergan, INC. | $263.63 | 2019-2020 | |
| Astellas Pharma US INC | $257.32 | 2019-2023 | Veozah |
| Amarin Pharma, INC. | $244.32 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $189.87 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $172.91 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $171.77 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $153.38 | 2019-2021 | |
| Exact Sciences Corporation | $133.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $105.73 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hoermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.